What are the side effects of the Bdparib 200 mg tablet?

Common side effects of the Bdparib 200mg tablet are constipation, muscle pain, swelling, nausea, diarrhea, infection, loss of appetite, hair loss, vomiting, and weakness.

How long does the treatment with the Bdparib 200 mg tablet last?

The doctor decides how long the treatment with the Bdparib 200mg tablet will continue, depending on the stage and health of the patient.

Can I drink alcohol while taking the Bdparib 200 mg tablet?

It is advised not to take alcohol while taking the Bdparib 200mg tablet, because consuming alcohol can cause serious side effects and can damage your liver badly. Consult your doctor if you have concerns or queries.

Is it safe to take this Bdparib 200 mg tablet during pregnancy or breastfeeding?

During pregnancy, it is not safe to take the Bdparib 200mg tablet, as it can cause harm to the unborn baby. Furthermore, during breastfeeding, this medicine must not be used. Please make sure to consult your healthcare provider regarding the same.

How does the Bdparib 200 mg tablet work?

Bdparib 200 mg tablet blocks the androgen receptor due to the presence of enzalutamide. It blocks testosterone from reaching prostate cancer cells. Testosterone production helps cancer cells grow, so by blocking the generation of this hormone, the growth of cancer cells can be shrunk. Bdparib 200 mg tablet belongs to the androgen receptor inhibitors.

What information should be told to the doctor before taking a Bdparib 200 mg tablet?

Inform the doctor if you are allergic to the ingredient present in the Bdparib 200 mg tablet, in case of high sugar level, pregnancy or breastfeeding, or a weakened immune system. A patient with a medical history or medication must discuss it with a doctor.

Is the Bdparib 200 mg tablet an antibiotic?

No, Bdparib 200mg tablet is an anti-cancer medication that contains enzalutamide, which is an androgen receptor inhibitor.

Can kidney patients use the Bdparib 200 mg tablet?

Bdparib 200 mg tablet blocks the androgen receptor due to the presence of enzalutamide. It blocks testosterone from reaching prostate cancer cells. Testosterone production helps cancer cells grow, so blocking its production can shrink cancer cell growth. Bdparib 200 mg belongs to the androgen receptor inhibitors.

Deal of the Day — limited-time pharmacy picks!Deal of the Day — today's spotlight pharmacy prices, refreshed daily.

Bdparib 200mg Tablet

Name: Bdparib 200mg Tablet
Brand: Bdparib
Price: 32650 INR
Availability: InStock
Rating: 4.86 (7 reviews)

Rx Required

Salt Composition: Rucaparib

Expiry Date: 01/2028

Price on Request

Inclusive of all taxes

▼

60 Tablets in Bottle

About The Product

Ovarian Cancer, Prostate cancer

The Bdparib 200 mg is a member of the class known as polyADP-ribose polymerase inhibitors. The active component of this anti-cancer medication is rucaparib. It is used to treat some forms of ovarian cancer, fallopian tube cancer (found in females), and primary peritoneal cancer (a layer of tissue lining the belly). In individuals with a certain gene mutation (BRCA), the bdparib 200mg is also used to treat some forms of cancer. Those who are allergic to Bdparib or any of its constituents should not take this cancer medication.

Uses

Bixel, K., & Hays, J.
L.
(2025).
Olaparib in the management of ovarian cancer.
Pharmacogenomics and personalized medicine, 127-135.
Dent, R.
A., Lindeman, G.
J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N.
J., & Carmichael, J.
(2023).
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer.
Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J.
A.
(2024).
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S.
B., Dean, E., Middleton, M.
R., & Molife, L.
R.
(2022).
An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib.
Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H.
(2025).
Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients.
Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.

Benefits

Bixel, K., & Hays, J. L.

(2025). Olaparib in the management of ovarian cancer.

Pharmacogenomics and personalized medicine, 127-135. Dent, R.

A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N.

J., & Carmichael, J. (2023).

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.

Luvero, D., Milani, A., & Ledermann, J. A.

(2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.

Therapeutic advances in medical oncology, 6(5), 229-239. Mateo, J., Moreno, V., Gupta, A., Kaye, S.

B., Dean, E., Middleton, M. R., & Molife, L.

R. (2022).

An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.

Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025).

Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.

Side Effects

Bixel, K., & Hays, J.
L.
(2025).
Olaparib in the management of ovarian cancer.
Pharmacogenomics and personalized medicine, 127-135.
Dent, R.
A., Lindeman, G.
J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N.
J., & Carmichael, J.
(2023).
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer.
Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J.
A.
(2024).
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S.
B., Dean, E., Middleton, M.
R., & Molife, L.
R.
(2022).
An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib.
Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H.
(2025).
Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients.
Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.

How To Use

Bixel, K., & Hays, J.
L.
(2025).
Olaparib in the management of ovarian cancer.
Pharmacogenomics and personalized medicine, 127-135.
Dent, R.
A., Lindeman, G.
J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N.
J., & Carmichael, J.
(2023).
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer.
Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J.
A.
(2024).
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S.
B., Dean, E., Middleton, M.
R., & Molife, L.
R.
(2022).
An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib.
Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H.
(2025).
Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients.
Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.

How It Works

Bixel, K., & Hays, J. L.

(2025). Olaparib in the management of ovarian cancer.

Pharmacogenomics and personalized medicine, 127-135. Dent, R.

A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N.

J., & Carmichael, J. (2023).

Luvero, D., Milani, A., & Ledermann, J. A.

(2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.

Therapeutic advances in medical oncology, 6(5), 229-239. Mateo, J., Moreno, V., Gupta, A., Kaye, S.

B., Dean, E., Middleton, M. R., & Molife, L.

R. (2022).

An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.

Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025).

Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.

Safety Advice

Alcohol

Drinking too much alcohol could damage a person's immunity and liver function. Alcohol consumption can cause dizziness, confusion, tiredness, and cognitive impairment, so it is advised not to consume alcohol while taking the Bdparib 200mg tablet.

Pregnancy

It is not advised to take the Bdparib 200mg tablet when pregnant because it affects the fetus. This is not for use in pregnant women.

Breast Feeding

Because there is a possibility that the Bdparib 200mg tablet could be transferred to the developing infant through the mother's breast milk, it is not advised to consume it while nursing. It is widely regarded as dangerous, and there is not enough evidence in the clinical data on its adverse impacts on infants.

Driving

Taking a Bdparib 200mg tablet while operating machinery may cause confusion or impair one's driving capacity. The capsule may cause neurological side effects, such as fever or feeling dizzy. Until you feel better, don't drive.

Kidney

People with kidney issues can use the Bdparib 200mg tablet after consulting with the doctor. It may harm the kidneys if taken as self-medication.

Liver

People with severe liver illness should not use the Bdparib 200mg tablet. Whereas people with mild liver disease can use this solution, but it must be regularly monitored. Use caution and alter the dosage of the Bdparib 200mg tablet as advised by your doctor.

FAQs

As soon as you remember, take the missed dose unless it's time for your next dose.

You should never take a double dose to make up for a missed one.

Reference

Bixel, K., & Hays, J. L.

(2025). Olaparib in the management of ovarian cancer.

Pharmacogenomics and personalized medicine, 127-135. Dent, R.

A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N.

J., & Carmichael, J. (2023).

Luvero, D., Milani, A., & Ledermann, J. A.

(2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.

Therapeutic advances in medical oncology, 6(5), 229-239. Mateo, J., Moreno, V., Gupta, A., Kaye, S.

B., Dean, E., Middleton, M. R., & Molife, L.

R. (2022).

An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.

Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025).

Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.

Certified Content

Written By

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

Last updated: 14 Sept 2026 | 04:41 PM (IST)

Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only

Not a substitute for professional medical advice

Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.

Read full medical disclaimer in Terms & Conditions